Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Kaoru Kubota"'
Autor:
Tae Iwasawa, Takaaki Tokito, Hirotsugu Kenmotsu, Shinobu Hosokawa, Takeharu Yamanaka, Satoshi Ikeda, Shunichiro Iwasawa, Yuki Sato, Kaoru Kubota, Hiroaki Okamoto, Toshihide Yokoyama, Isamu Okamoto, Takashi Ogura, Naoki Furuya, Terufumi Kato, Toshiyuki Harada
Publikováno v:
Journal of Thoracic Oncology
Introduction Interstitial pneumonia (IP) is one of the most common and poor prognostic comorbidities in patients with NSCLC and a known risk factor for pneumonitis. Atezolizumab monotherapy is an established treatment for recurrent NSCLC and reported
Autor:
Kazuhiko Yamada, Yoichi Nakamura, Sakiko Otani, Kazuma Kishi, Takeharu Yamanaka, Hiroshi Tanaka, Haruhiro Saito, Kaoru Kubota, Tsuneo Shimokawa, Yuichi Takiguchi, Hiroaki Okamoto, Toshihiro Misumi, Terufumi Kato, Yukio Hosomi, Daijiro Harada, Takashi Kasai
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 2, Pp 626-633 (2021)
Cancer Medicine, Vol 10, Iss 2, Pp 626-633 (2021)
Cisplatin‐based chemoradiotherapy is considered standard treatment for unresectable locally advanced non‐small‐cell lung cancer (LA‐NSCLC). This study examined two regimens of chemotherapy in concurrent chemoradiation. Eligible patients with
Autor:
Kaoru Kubota, Masaru Nishitsuji, Masahiro Seike, Koichi Hagiwara, Masahiro Ando, Makiko Yomota, Akihiko Miyanaga, Mitsunori Hino, Tsuneo Shimokawa, Rintaro Noro, Akihiko Gemma, Jiro Usuki, Kunihiko Kobayashi
Publikováno v:
Thoracic Cancer. 11:1876-1884
Background Pleurodesis is the standard of care for non-small cell lung cancer (NSCLC) patients with symptomatic malignant pleural effusion (MPE). However, there is no standard management for MPE uncontrolled by pleurodesis. Most patients with unsucce
Autor:
Yuji Minegishi, Kaoru Kubota, Akihiko Gemma, Natsuki Takano, Yoshinobu Saito, Kakeru Hisakane, Satoshi Takahashi, Takeru Kashiwada, Toru Tanaka, Teppei Sugano, Akihiko Miyanaga, Susumu Takeuchi, Masahiro Seike, Rintaro Noro, Yasuhiro Terasaki
Publikováno v:
Thoracic Cancer, Vol 11, Iss 4, Pp 1052-1060 (2020)
Thoracic Cancer
Thoracic Cancer
Background Interstitial lung disease (ILD) induced by immune checkpoint inhibitors (ICIs) is a potentially life-threatening adverse event. The purpose of this study was to evaluate whether the development of immune-related adverse events (irAEs), esp
Autor:
John G. Edwards, Kari Chansky, Paul Van Schil, Andrew G. Nicholson, Souheil Boubia, Elisabeth Brambilla, Jessica Donington, Françoise Galateau-Sallé, Hans Hoffmann, Maurizio Infante, Mirella Marino, Edith M. Marom, Jun Nakajima, Marcin Ostrowski, William D. Travis, Ming-Sound Tsao, Yasushi Yatabe, Dorothy J. Giroux, Lynn Shemanski, John Crowley, Marc Krasnik, Hisao Asamura, Ramón Rami-Porta, Valerie Rusch, Luiz Henrique Araujo, David Beer, Pietro Bertoglio, Ricardo Beyruti, Andrea Bille, Vanessa Bolejack, James D. Brierley, A.K. Cangir, David Carbone, Gail Darling, Frank Detterbeck, Xavier Benoit D’Journo, Jessica Donnington, Wilfried Eberhardt, John Edwards, Jeremy Erasmus, Conrad Falkson, Wentao Fang, Dean Fennell, Kwun Fong, Françoise Galateau-Salle, Oliver Gautschi, Ritu Gill, Dorothy Giroux, Meredith Giuliani, Jin Mo Goo, Seiki Hasegawa, Fred Hirsch, Hans Hoffman, Wayne Hofstetter, James Huang, Philippe Joubert, Kemp Kernstine, Keith Kerr, Young Tae Kim, Hong Kwan Kim, Hedy Kindler, Yolande Lievens, Hui Liu, Donald E. Low, Gustavo Lyons, Heber MacMahon, Edith Marom, José-María Matilla, Jan van Meerbeeck, Luis M. Montuenga, Andrew Nicholson, Katie Nishimura, Anna Nowak, Isabelle Opitz, Meinoshin Okumura, Raymond U. Osarogiagbon, Harvey Pass, Marc de Perrot, Helmut Prosch, David Rice, Andreas Rimner, Enrico Ruffini, Shuji Sakai, Navneet Singh, Amy Stoll-D’Astice, Francisco Su´rez, Ricardo M. Terra, Ming S. Tsao, Paula Ugalde, David Waller, Shun-ichi Watanabe, Jacinta Wiens, Ignacio Wistuba, Liyan Jiang, Kaoru Kubota, Akif Turna, Benny Weksler, Maria Teresa Tzukazan, Martin Tammemägi, Charles Powell, David Naidich, Hongxu Liu, Samuel Armato, Alex Brunelli, Giuseppe Cardillo, Elizabeth David, Brigitte Fournier, Mark Krasnik, Kauro Kubota, Catherine Labbe, Eric Lim, Paul Martin Putora, Gaetano Rocco, Pier Luigi Filosso, Kazuya Kondo, Dong Kwan Kim, Giuseppe Giaccone, Marco Lucchi, Thomas Rice, Mark Ferguson, Prasad Adsusmilli, William Travis, Francisco Suárez, Kaura Kubota, Hisao Asamura Shun-ichi, Watanabe, Edith Marom Ramón, Rami-Porta, Ming Tsao, Ming Tsao Shun-ichi, Watanabe, Meredith Guiliani, James Brierley, Ricardo Terra, Ray Osarogiagbon, Luis Montuenga, Hongwei Wang, Françoise Galateau, Jim Mo Goo, Bill Travis, Jose Maria Matilla, Carolle St. Pierre, Ma Teresa Tzukazan, Nicholas Girard, Andreas Rimmer, Francoise Galateau, Prasad Adusumilli, Xavier D’Journo, Donald Low, Adam Rosenthal
Publikováno v:
Journal of theoretical biology
Journal of thoracic oncology
Journal of thoracic oncology
Objective: Our aim was to validate the prognostic relevance in NSCLC of potential residual tumor (R) descriptors, including the proposed International Association for the Study of Lung Cancer definition for uncertain resection, referred to as R(un).
Autor:
Kageaki Watanabe, Yusuke Okuma, Makiko Yomota, Akihiko Gemma, Shoko Kawai, Yasuhiro Kato, Tatsuru Okamura, Yukio Hosomi, Kaoru Kubota, Masahiro Seike
Publikováno v:
Journal of Thoracic Disease. 11:2350-2360
BACKGROUND: Osimertinib exhibits good efficacy in patients with T790M-positive non-small cell lung cancer (NSCLC) and acquired resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs). Compared with the clinical trials,
Autor:
Kaoru Kubota, Yuichiro Ohe, Hidetoshi Hayashi, Tomohide Tamura, Tsuneo Shimokawa, Makoto Nishio, Toyoaki Hida, Tomohisa Baba, Kazutaka Miyadera, Kazuo Kasahara, Haruyasu Murakami, Hiroshi Sakai, Fumio Imamura, Yukio Hosomi
Publikováno v:
Investigational New Drugs
Summary Purpose We investigated the safety, tolerability, pharmacokinetics, and efficacy of TAS-121, a novel, potent, and highly selective third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in Japanese patients wit
Autor:
Natsuki Takano, Rintaro Noro, Akihiko Gemma, Teppei Sugano, Masahiro Seike, Kakeru Hisakane, Shingo Kitagawa, Takehiro Tozuka, Kenichi Kobayashi, Yuji Minegishi, Kaoru Kubota, Tomomi Kato, Satoshi Takahashi, Shinobu Kunugi, Susumu Takeuchi, Yoshinobu Saito, Takeru Kashiwada
Publikováno v:
OncoTargets and Therapy. 11:5601-5605
Immuno-checkpoint inhibitors (ICI) have become an effective treatment option for non-small-cell lung cancer patients. However, ICI therapy was reported to be less effective in patients with epidermal growth factor receptor (EGFR) mutations than in th
Autor:
Marina Chiara Garassino, Byoung-Chul Cho, Joo-Hang Kim, Julien Mazières, Johan Vansteenkiste, Hervé Lena, Jesus Corral Jaime, Jhanelle E Gray, John Powderly, Christos Chouaid, Paolo Bidoli, Paul Wheatley-Price, Keunchil Park, Ross A Soo, Yifan Huang, Catherine Wadsworth, Phillip A Dennis, Naiyer A Rizvi, Luis Paz-Ares Rodriguez, Silvia Novello, Sandrine Hiret, Peter Schmid, Eckart Laack, Raffaele Califano, Makoto Maemondo, Sang-We Kim, Jamie Chaft, David Vicente Baz, Thierry Berghmans, Dong-Wan Kim, Veerle Surmont, Martin Reck, Ji-Youn Han, Esther Holgado Martin, Cristobal Belda Iniesta, Yuichiro Oe, Antonio Chella, Akhil Chopra, Gilles Robinet, Hector Soto Parra, Michael Thomas, Parneet Cheema, Nobuyuki Katakami, Wu-Chou Su, Young-Chul Kim, Juergen Wolf, Jong-Seok Lee, Hideo Saka, Michele Milella, Inmaculada Ramos Garcia, Anne Sibille, Takashi Yokoi, Eun Joo Kang, Shinji Atagi, Ernst Spaeth-Schwalbe, Makoto Nishio, Fumio Imamura, Nashat Gabrail, Remi Veillon, Sofie Derijcke, Tadashi Maeda, Dylan Zylla, Kendra Kubiak, Armando Santoro, Ma. Noemi Uy, Sarayut Lucien Geater, Antoine Italiano, Dariusz Kowalski, Fabrice Barlesi, Yuh-Min Chen, David Spigel, Busyamas Chewaskulyong, Ramon Garcia Gomez, Rosa Alvarez Alvarez, Chih-Hsin Yang, Te-Chun Hsia, Fabrice Denis, Hiroshi Sakai, Mark Vincent, Koichi Goto, Joaquim Bosch-Barrera, Glen Weiss, Jean-Luc Canon, Christian Scholz, Massimo Aglietta, Hirotsugu Kemmotsu, Koichi Azuma, Penelope Bradbury, Ronald Feld, Abraham Chachoua, Jacek Jassem, Rosalyn Juergens, Ramon Palmero Sanchez, Albert Malcolm, Nandagopal Vrindavanam, Kaoru Kubota, Cornelius Waller, David Waterhouse, Bruno Coudert, Zsuzsanna Mark, Miyako Satouchi, Gee-Chen Chang, Christian Herzmann, Arvind Chaudhry, Selvaraj Giridharan, Paul Hesketh, Norihiko Ikeda, Ralph Boccia, Nichola Iannotti, Missak Haigentz, John Reynolds, John Querol, Kazuhiko Nakagawa, Shunichi Sugawara, Eng Huat Tan, Tomonori Hirashima, Scott Gettinger, Terufumi Kato, Koji Takeda, Oscar Juan Vidal, Andrea Mohn-Staudner, Amit Panwalkar, Davey Daniel, Kunihiko Kobayashi, Guia Elena Imelda Ladrera, Clemens Schulte, Martin Sebastian, Marketa Cernovska, Helena Coupkova, Libor Havel, Norbert Pauk, Joginder Singh, Shuji Murakami, Tibor Csoszi, Gyorgy Losonczy, Allan Price, Ian Anderson, Mussawar Iqbal, Vamsee Torri, Erzsebet Juhasz, Saleem Khanani, Leona Koubkova, Benjamin Levy, Ray Page, Csaba Bocskei, Lucio Crinò, David Einspahr, Christopher Hagenstad, Necy Juat, Lindsay Overton, Mitchell Garrison, Zsuzsanna Szalai
Publikováno v:
Lancet Oncology
Lancet Oncology, 2020, 19 (4), pp.521-536. ⟨10.1016/s1470-2045(18)30144-x⟩
Lancet Oncol
Lancet Oncology, 2020, 19 (4), pp.521-536. ⟨10.1016/s1470-2045(18)30144-x⟩
Lancet Oncol
Background: Immune checkpoint inhibitors are a new standard of care for patients with advanced non-small-cell lung cancer (NSCLC) without EGFR tyrosine kinase or anaplastic lymphoma kinase (ALK) genetic aberrations (EGFR−/ALK−), but clinical bene
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00025c91c5f85bf7d8b98d17aae85fd1
https://hal.u-pec.fr/hal-04145965/document
https://hal.u-pec.fr/hal-04145965/document
Autor:
Ferdinandos Skoulidis, Sarah B. Goldberg, Edward B. Garon, Alex A. Adjei, Scott N. Gettinger, Martin Reck, Patrick M. Forde, Luis Paz-Ares, Myung-Ju Ahn, Jordi Remon, Leora Horn, Roy S. Herbst, Laura Mezquita, Kurt A. Schalper, Fabrice Barlesi, Sanjay Popat, Francesco Passiglia, Shun Lu, Kaoru Kubota, Giorgio V. Scagliotti
In the past 10 years, a deeper understanding of the immune landscape of cancers, including immune evasion processes, has allowed the development of a new class of agents. The reactivation of host antitumor immune response offers the potential for lon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be74416fd64abf5ca5b7943b4a81d888
http://hdl.handle.net/2318/1770085
http://hdl.handle.net/2318/1770085